User:Mr. Ibrahem/Tebentafusp

Tebentafusp, sold under the brand name Kimmtrak, is an medication used to treat a type of eye cancer, known as uveal melanoma. It is used in HLA-A*02:01-positive cases that cannot be managed by surgery alone. It is given by injection into a vein. Due to the risk of side effects nearly a day of monitoring is required after the initial doses.

Common side effects include cytokine release syndrome, rash, fever, itching, tiredness, nausea, abdominal pain, swelling, low blood pressure, dry skin, headache, and vomiting. Use in pregnancy may harm the baby. It is a bispecific gp100 peptide-HLA-directed CD3 T cell engager.

Tebentafusp was approved for medical use in the United States and Europe in 2022. In the United States the medication costs about 18,800 USD per dose. While available in the United Kingdom, the cost is yet to be determined.